ProMetic Life Sciences Inc. (TSE:PLI)‘s stock had its “hold” rating reissued by investment analysts at BLOOM BURTON&CO in a research report issued on Thursday.

A number of other research firms also recently weighed in on PLI. Scotiabank restated an “outperform” rating and issued a C$5.00 target price on shares of ProMetic Life Sciences in a research report on Thursday. Royal Bank Of Canada restated an “outperform” rating on shares of ProMetic Life Sciences in a research report on Thursday. TD Securities restated a “speculative buy” rating and issued a C$4.50 target price on shares of ProMetic Life Sciences in a research report on Wednesday, September 28th. Finally, CIBC cut their target price on ProMetic Life Sciences from C$5.00 to C$4.85 in a research report on Thursday, August 25th. Two analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. The company presently has a consensus rating of “Buy” and an average price target of C$4.84.

Analyst Recommendations for ProMetic Life Sciences (TSE:PLI)

Shares of ProMetic Life Sciences (TSE:PLI) opened at 3.10 on Thursday. The stock’s market cap is $1.87 billion. The stock has a 50 day moving average price of $2.93 and a 200-day moving average price of $3.01. ProMetic Life Sciences has a 12 month low of $1.67 and a 12 month high of $3.62.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at

About ProMetic Life Sciences

ProMetic Life Sciences Inc (ProMetic) is a Canada-based biopharmaceutical company. The Company has two segments: Small Molecule Therapeutics and Protein Technology. The Company offers its technology platform for large-scale drug purification of biologics, drug development, proteomics and the elimination of pathogens to various industries, and uses its own affinity technology that provides for extraction and purification of therapeutic proteins from human plasma in order to develop therapeutics and orphan drugs.

Receive News & Ratings for ProMetic Life Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProMetic Life Sciences Inc. and related companies with's FREE daily email newsletter.